Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03982004CT.gov Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT04270149CT.gov Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02297698CT.gov Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients | — | Completed | — | — | — |
NCT01570036CT.gov Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | — | Completed | — | — | — |
NCT03014076CT.gov Immunotherapy Vaccine and Herceptin in Breast Cancer | — | Completed | — | — | — |
NCT00524277CT.gov Vaccine Therapy in Treating Patients With Breast Cancer | — | Completed | — | — | — |
NCT00499083CT.gov Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) | — | Completed | — | — | — |
NCT00266110CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00254592CT.gov Neoadjuvant Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00128622CT.gov Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT00107211CT.gov Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast | — | Completed | — | — | — |
NCT00256243CT.gov Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer | — | Completed | — | — | — |
NCT00088985CT.gov Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer | — | Terminated | — | — | — |
NCT00854789CT.gov Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer | — | Completed | — | — | — |
NCT00429104CT.gov Herceptin and GM-CSF for Metastatic Breast Cancer | — | Completed | — | — | — |
NCT00841399CT.gov Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients | — | Completed | — | — | — |
NCT00005956CT.gov Biological Therapy in Treating Patients With Advanced Cancer | — | Completed | — | — | — |
NCT00001239CT.gov Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Gm-Csf (this asset) | Washington University School of Medicine | P2 | B · 58 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Gm-Csf
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P4 | BBB · 74 |
| Melanoma | — | P4 | BBB · 74 |
| Uveal Melanoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Gm-Csf in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gm-csf-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →